Cytek Biosciences, Inc. CTKB
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- +21.39%
- 1 year
- +60.47%
- Open
- 6.26
- Prev close
- 6.30
- Mkt cap
- 796.80M
- Vol
- 1.87M
- Avg vol
- 1.21M
- EPS
- -0.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.05
- High
- 6.28
- Forward P/E
- 107.67
- Beta
- 1.32
- Short ratio
- 4.50
- Inst. own
- 59.02%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2024
- 50-d avg
- 6.03
- 200-d avg
- 5.92
- 1y target
- 8.40
3M chart
Signals (23)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 29, 2026 | 3 days ago |
| MACD: Buy Signal | Oct 26, 2026 | 6 days ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 7, 2026 | 3 weeks ago |
| RSI: Overbought | Oct 2, 2026 | 1 month ago |
| RSI: Overbought | Sep 22, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 4, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
Key statistics
- Market cap
- 832.12M
- Enterprise value
- 550.82M
- Trailing P/E
- 0.00
- Forward P/E
- 107.67
- PEG ratio
- 0.00
- Price / sales
- 4.14
- Price / book
- 2.18
- EPS (TTM)
- -0.08
- Beta
- 1.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -5.05%
- Revenue (TTM)
- 201.21M
- Revenue growth
- 7.30%
- Free cash flow
- 40.66M
- Total cash
- 277.78M
- Total debt
- 14.52M
- Return on equity
- -2.54%
- Shares outstanding
- 128.81M
- Short % of float
- 3.95%
- 50-day average
- 6.03
- 200-day average
- 5.92
Analyst view
Consensus: buy
- Target (low)
- 7.00
- Target (mean)
- 8.40
- Target (high)
- 9.00
- Strong buy2
- Buy2
- Hold2
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate 0.11333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | -0.02 | 0.01 | +0.03 | +150.00% |
| Aug 6, 2024 | Jun 1, 2024 | -0.03 | — | — | — |
| Aug 6, 2024 | Jun 1, 2024 | -0.03 | -0.08 | -0.05 | -166.67% |
| May 8, 2024 | Mar 1, 2024 | -0.05 | -0.05 | 0.00 | 0.00% |
| May 8, 2024 | Mar 1, 2024 | -0.05 | — | — | — |
| Nov 7, 2023 | Sep 1, 2023 | 0.02 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | Piper Sandler | main | Overweight | Overweight |
| Aug 13, 2024 | Piper Sandler | main | Overweight | Overweight |
| May 13, 2024 | Piper Sandler | main | Overweight | Overweight |
| Mar 6, 2024 | Piper Sandler | main | Overweight | Overweight |
| Feb 29, 2024 | Goldman Sachs | main | Buy | Buy |
| Dec 14, 2023 | Stephens & Co. | init | — | Overweight |
About Cytek Biosciences, Inc.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- cytekbio.com
News
- Cytek Biosciences to Participate in Upcoming Investor Conferences
- Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
- Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
- Cytek Biosciences (NASDAQ:CTKB) Sets New 12-Month High – Here’s What Happened
- 1,315,332 Shares in Cytek Biosciences, Inc. $CTKB Acquired by Bank of America Corp DE
- Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
- Critical Survey: Revvity (NYSE:RVTY) vs. Cytek Biosciences (NASDAQ:CTKB)
- Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
- Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
Your note
Sign in to keep a note on CTKB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARNETT VALERIE | Officer | Conversion of Exercise of derivative security | Nov 17, 2024 | 62,850 |
| BUSQUE PHILIPPE | Officer | Conversion of Exercise of derivative security | Nov 17, 2024 | 12,871 |
| GARLAND JONATHAN TODD | Officer | Conversion of Exercise of derivative security | Aug 17, 2023 | 8,763 |
| HOLDER MICHAEL | Director | Conversion of Exercise of derivative security | Nov 17, 2024 | 3,635 |
| JEANMONOD PATRIK | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 10, 2024 | 97,465 |
| JIANG WENBIN | Chief Executive Officer | Conversion of Exercise of derivative security | Nov 17, 2024 | 5,187,640 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 14.36% | 18,492,291 | 119.46M | Sep 29, 2024 |
| Vanguard Group Inc | 9.14% | 11,778,054 | 76.09M | Sep 29, 2024 |
| Brown Capital Management, LLC | 7.37% | 9,493,474 | 61.33M | Sep 29, 2024 |
| HHLR Advisors, LTD | 5.17% | 6,657,030 | 43.00M | Sep 29, 2024 |
| State Street Corporation | 3.24% | 4,167,501 | 26.92M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.07% | 2,668,004 | 17.24M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | 5.29% | 6,819,167 | 44.05M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.70% | 3,474,084 | 22.44M | Sep 29, 2024 |
| Brown Capital Management Small Company Fund | 2.69% | 3,464,590 | 22.38M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.42% | 3,121,619 | 20.17M | Oct 30, 2024 |
| Vanguard Small-Cap Index Fund | 2.05% | 2,637,310 | 17.04M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.20% | 1,542,181 | 9.96M | Sep 29, 2024 |